* [[Hiperkolesterolemia]]<ref>{{Cite journal|last=McCrindle|first=Brian W|last2=Ose|first2=Leiv|last3=Marais|first3=A.David|date=2003-07|title=Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial|url=https://linkinghub.elsevier.com/retrieve/pii/S0022347603001860|journal=The Journal of Pediatrics|language=en|volume=143|issue=1|pages=74–80|doi=10.1016/S0022-3476(03)00186-0}}</ref> ([[ Hiperkolesterolemia familial|familial heterozigot dan nonfamilial]]) dan [[dislipidemia]] campuran ([[ Klasifikasi Fredrickson|Fredrickson tipe IIa]] dan [[ Klasifikasi Fredrickson|IIb]]) untuk mengurangi [[Kolesterol|kadar kolesterol]] total, [[Lipoprotein densitas rendah|LDL-C]],<ref name="Nissen_2006"/> [[ Apolipoprotein B|apo-B]],<ref>{{Cite journal|last=Nawrocki|first=James W.|last2=Weiss|first2=Stuart R.|last3=Davidson|first3=Michael H.|last4=Sprecher|first4=Dennis L.|last5=Schwartz|first5=Sherwyn L.|last6=Lupien|first6=Paul-J.|last7=Jones|first7=Peter H.|last8=Haber|first8=Harry E.|last9=Black|first9=Donald M.|date=1995-05|title=Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor|url=https://www.ahajournals.org/doi/10.1161/01.ATV.15.5.678|journal=Arteriosclerosis, Thrombosis, and Vascular Biology|language=en|volume=15|issue=5|pages=678–682|doi=10.1161/01.ATV.15.5.678|issn=1079-5642}}</ref> [[trigliserida]],<ref>{{Cite web|url=https://pubmed.ncbi.nlm.nih.gov/8531308/|title=Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia|last=Rg|first=Bakker-Arkema|last2=Mh|first2=Davidson|date=1996-01-10|website=JAMA|language=en|pmid=8531308|access-date=2020-05-25|last3=Rj|first3=Goldstein|last4=J|first4=Davignon|last5=Jl|first5=Isaacsohn|last6=Sr|first6=Weiss|last7=Lm|first7=Keilson|last8=Wv|first8=Brown|last9=Vt|first9=Miller}}</ref> dan [[Protein C-reaktif|CRP]],<ref>{{Cite web|url=https://pubmed.ncbi.nlm.nih.gov/16908955/|title=The Anti-Atherosclerotic Effects of Lipid Lowering With Atorvastatin in Patients With Hypercholesterolemia|last=K|first=Ozaki|last2=T|first2=Kubo|date=2006 Aug|website=Journal of atherosclerosis and thrombosis|language=en|pmid=16908955|access-date=2020-05-25|last3=R|first3=Imaki|last4=H|first4=Shinagawa|last5=H|first5=Fukaya|last6=K|first6=Ohtaki|last7=S|first7=Ozaki|last8=T|first8=Izumi|last9=Y|first9=Aizawa}}</ref> serta meningkatkan level [[Lipoprotein densitas tinggi|HDL]].
* [[ Hiperkolesterolemia familial|Hiperkolesterolemia familial heterozigot]]<ref>{{Cite nameweb|url="pmid12915827"https://pubmed.ncbi.nlm.nih.gov/12915827/|title=Efficacy and Safety of Atorvastatin in Children and Adolescents With Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial|last=Bw|first=McCrindle|last2=L|first2=Ose|date=2003 Jul|website=The Journal of pediatrics|language=en|pmid=12915827|access-date=2020-05-25|last3=Ad|first3=Marais}}</ref> pada [[Pediatri|anak-anak]]
* [[ Hiperkolesterolemia familial|Hiperkolesterolemia familial homozigot]]<ref>{{Cite web|url=https://pubmed.ncbi.nlm.nih.gov/12915827/|title=Efficacy and Safety of Atorvastatin in Children and Adolescents With Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial|last=Bw|first=McCrindle|last2=L|first2=Ose|date=2003 Jul|website=The Journal of pediatrics|language=en|pmid=12915827|access-date=2020-05-25|last3=Ad|first3=Marais}}</ref><ref>{{Cite web|url=https://pubmed.ncbi.nlm.nih.gov/9301631/|title=Atorvastatin: An Effective Lipid-Modifying Agent in Familial Hypercholesterolemia|last=Ad|first=Marais|last2=Jc|first2=Firth|date=1997 Aug|website=Arteriosclerosis, thrombosis, and vascular biology|language=en|pmid=9301631|access-date=2020-05-25|last3=Me|first3=Bateman|last4=P|first4=Byrnes|last5=C|first5=Martens|last6=J|first6=Mountney}}</ref>
